ArticleTransboundary and emerging diseases2026
Conserved Linear Epitopes in the VP1 Protein of Foot-and-Mouth Disease Virus Serotype SAT2: Identification and Characterization.
Article in Transboundary and emerging diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Conserved Linear Epitopes in the VP1 Protein of Foot-and-Mouth Disease Virus Serotype SAT2: Identification and Characterization.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Foot-and-mouth disease virus (FMDV) serotype Southern African Territories 2 (SAT2), historically endemic to sub-Saharan Africa, has recently expanded its geographical range to the Middle East, posing a significant transboundary threat to global livestock industries. Characterized by high genetic diversity encompassing 14 distinct topotypes, SAT2 poses a challenge to reliable serological diagnosis and underscores the need for conserved, serotype-specific antigenic targets. In this study, we aimed to identify such targets by mapping linear epitopes in the VP1 capsid protein using three monoclonal antibodies (mAbs; 3B2, 6F2, and 2F11) raised against SAT2 VP1. Epitopes were mapped through sequential truncation and alanine‑scanning mutagenesis, and their conservation was assessed across VP1 sequences from 53 SAT strains (35 SAT2, 13 SAT1, and 5 SAT3). The epitope recognized by mAb 3B2 was identified as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.